Literature DB >> 29171096

Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure.

Michèle Bally1,2, Marie-Eve Beauchamp2, Michal Abrahamowicz2,3, Lyne Nadeau2, James M Brophy2,3,4.   

Abstract

PURPOSE: Real-life use of nonsteroidal anti-inflammatory drugs (NSAIDs) is dynamic. This study aimed to characterize the temporal association between time-varying NSAID exposure and acute myocardial infarction (MI).
METHODS: Nested case-control analyses were conducted on a Quebec administrative health cohort. NSAID dose, confounders, and outcome status were determined for each day of follow-up. To better account for dose and timing of past exposures, flexible weighted cumulative exposure models were also fitted.
RESULTS: The cohort consisted of 233 816 older adults including 21 256 acute MI cases. Dose-related increased risks of MI were found with current use of all NSAIDs. In models not accounting for duration of use, ORs (95%CI) for the most common current daily dose vs. no current exposure were: celecoxib 200 mg: 1.16 (1.10, 1.22), diclofenac 150 mg: 1.59 (1.38, 1.84), ibuprofen 1200 mg: 1.42 (1.17, 1.74), naproxen 750 mg: 1.38 (1.21, 1.58), and rofecoxib 25 mg: 1.54 (1.43, 1.66). Weighted cumulative exposure models confirmed that all NSAIDs-including naproxen-are associated with an increased risk of MI and suggested that doses taken up to 3 weeks ago for rofecoxib, ibuprofen, and naproxen and up to 75 days ago for diclofenac and celecoxib may contribute to the current MI risk. However, the celecoxib risk seems to require continuous use for more than 30 days, whereas for other NSAIDs, a heightened MI risk occurs within 7 days.
CONCLUSIONS: Weighted cumulative exposure analysis uncovered NSAID-specific differences in the immediate MI risk and how this risk seems to accumulate. KEY POINTS Accurate assessment of drug safety requires an etiologically correct model encompassing all relevant aspects of exposure. Weighted cumulative exposure models suggest that the relative importance of past doses on the risk of MI differs among NSAIDs. All common NSAIDs are associated with an increased MI risk. Celecoxib MI risk seems to depend on continuously using the drug for more than 30 days, whereas for ibuprofen, rofecoxib, diclofenac, and naproxen, a heightened MI risk occurs within 7 days of use.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  acute myocardial infarction (MI); cumulative effects; nonsteroidal anti-inflammatory drugs (NSAIDs); pharmacoepidemiology

Mesh:

Substances:

Year:  2017        PMID: 29171096     DOI: 10.1002/pds.4358

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  10 in total

Review 1.  Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.

Authors:  Nicholas Moore
Journal:  Drug Saf       Date:  2020-04       Impact factor: 5.606

Review 2.  Pharmacological Management of Acute Endodontic Pain.

Authors:  Asma A Khan; Anibal Diogenes
Journal:  Drugs       Date:  2021-10-07       Impact factor: 9.546

3.  Acute anterior myocardial infarction during myopericarditis treatment in a very young adult.

Authors:  Alparslan Kurtul; Fatih Şen; Özkan Bekler
Journal:  Anatol J Cardiol       Date:  2020-06       Impact factor: 1.596

4.  Studying additive interaction in a healthcare database: Case study of NSAIDs, cardiovascular profiles, and acute myocardial infarction.

Authors:  Michèle Bally; Lyne Nadeau; James M Brophy
Journal:  PLoS One       Date:  2018-08-10       Impact factor: 3.240

Review 5.  Cyclo-Oxygenase (COX) Inhibitors and Cardiovascular Risk: Are Non-Steroidal Anti-Inflammatory Drugs Really Anti-Inflammatory?

Authors:  Shanzana Khan; Karen L Andrews; Jaye P F Chin-Dusting
Journal:  Int J Mol Sci       Date:  2019-08-30       Impact factor: 5.923

6.  Kounis Syndrome: Dexketoprofen-Associated ST-Elevation Myocardial Infarction.

Authors:  Aytekin Aksakal; Zeki Şimşek; Diyar Köprülü; Uğur Arslan
Journal:  Eur J Case Rep Intern Med       Date:  2021-11-12

Review 7.  East meets West: current practices and policies in the management of musculoskeletal aging.

Authors:  Weibo Xia; Cyrus Cooper; Mei Li; Ling Xu; Rene Rizzoli; Mei Zhu; Hua Lin; John Beard; Yue Ding; Wei Yu; Etienne Cavalier; Zhenlin Zhang; John A Kanis; Qun Cheng; Quimei Wang; Jean-Yves Reginster
Journal:  Aging Clin Exp Res       Date:  2019-08-02       Impact factor: 3.636

8.  Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements.

Authors:  Alberto Migliore; Gianfranco Gigliucci; Liudmila Alekseeva; Sachin Avasthi; Raveendhara R Bannuru; Xavier Chevalier; Thierry Conrozier; Sergio Crimaldi; Nemanja Damjanov; Gustavo Constantino de Campos; Demirhan Diracoglu; Gabriel Herrero-Beaumont; Giovanni Iolascon; Ruxandra Ionescu; Natasa Isailovic; Jörg Jerosch; Jorge Lains; Emmanuel Maheu; Souzi Makri; Natalia Martusevich; Marco Matucci Cerinc; Mihaela Micu; Karel Pavelka; Robert J Petrella; Umberto Tarantino; Raghu Raman
Journal:  Ther Adv Musculoskelet Dis       Date:  2019-12-19       Impact factor: 5.346

9.  Quality of reporting of drug exposure in pharmacoepidemiological studies.

Authors:  Mirjam Hempenius; Kim Luijken; Anthonius de Boer; Olaf Klungel; Rolf Groenwold; Helga Gardarsdottir
Journal:  Pharmacoepidemiol Drug Saf       Date:  2020-05-11       Impact factor: 2.890

Review 10.  Non-steroidal anti-inflammatory drugs in the pharmacological management of osteoarthritis in the very old: prescribe or proscribe?

Authors:  Christian Cadet; Emmanuel Maheu
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-06-18       Impact factor: 5.346

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.